Ionis' Dawnzera reduces HAE attack rates 95% over two years in extension study
IONS•Ionis said Dawnzera reduced hereditary angioedema attack rates by 95% over two years in an extension study, with results showing sustained reductions on dosing every four or eight weeks.
1. Extension study results
OASISplus extension results showed sustained reductions in hereditary angioedema attacks with Dawnzera (donidalorsen) dosed every four or eight weeks. Patients who switched from other long-term preventive therapies maintained lower attack rates than on their prior treatments over two years. No new safety signals emerged; most adverse events were mild or moderate, and there were no serious treatment-related events.
